Innoviva (INVA) Raw Materials (2012 - 2026)
Innoviva's (INVA) quarterly Raw Materials came in at $17.5 million in Q1 2026, up 64.44% YoY from $10.6 million in Q1 2025, and up 6.93% on a QoQ basis from $16.3 million in Q4 2025.
Analysis
Innoviva (INVA) Raw Materials (2012 - 2026) Analysis & Trends
Innoviva (INVA) has 8 years of Raw Materials data on file, last reported at $17.5 million in Q1 2026.
- Quarterly Raw Materials rose 64.44% year-over-year to $17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.5 million (up 64.44% YoY) and the FY2025 annual result came in at $16.3 million, up 46.95% from the prior year.
- Raw Materials improved to $17.5 million in Q1 2026, from $16.3 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $17.5 million in Q1 2026 to a low of $5.8 million in Q3 2022.
- A 5-year average of $10.4 million and a median of $9.5 million in 2024 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2023 — Raw Materials surged 95.54% — and 2024, when it slipped 1.28%.
- Tracing INVA's Raw Materials over 5 years: stood at $5.8 million in 2022, then surged by 95.54% to $11.3 million in 2023, then slipped by 1.28% to $11.1 million in 2024, then soared by 46.95% to $16.3 million in 2025, then climbed by 6.93% to $17.5 million in 2026.
- The last three Raw Materials figures came in at $17.5 million (Q1 2026), $16.3 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.72 Mn |
| Mar 31, 2026 | 17.46 Mn |
| Dec 31, 2025 | 16.33 Mn |
| Sep 30, 2025 | 14.37 Mn |
| Jun 30, 2025 | 10.55 Mn |
| Mar 31, 2025 | 10.62 Mn |
| Dec 31, 2024 | 11.11 Mn |
| Sep 30, 2024 | 9.53 Mn |
| Jun 30, 2024 | 9.53 Mn |
| Mar 31, 2024 | 9.53 Mn |
| Dec 31, 2023 | 11.26 Mn |
| Sep 30, 2023 | 8.86 Mn |
| Jun 30, 2023 | 8.86 Mn |
| Mar 31, 2023 | 5.76 Mn |
| Dec 31, 2022 | 5.76 Mn |
| Sep 30, 2022 | 5.76 Mn |
| Mar 31, 2014 | 4.00 Mn |
| Dec 31, 2013 | 5.14 Mn |
| Sep 30, 2013 | 4.08 Mn |
| Jun 30, 2013 | 3.53 Mn |